Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
Bacsur P., Shaham D., Serclova Z., Resál T., Farkas B., Sarlós P.
Retrospective Study with a reported sample of 223 on Autoimmune Research, published in Aliment Pharmacol Ther (2024) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Aliment Pharmacol Ther (2024)
- Country
- England
- Reported sample size
- 223
- Source database
- PubMed
- PMID
- 39468719
- DOI
- 10.1111/apt.18359
Abstract (original English)
Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose-derived mesenchymal stem cell treatment are contradicting, and real-world evidence is lacking. To examine the usability of darvadstrocel therapy in managing perianal CD. We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression. Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported. Effectiveness data were higher than in
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ARandomized Controlled TrialPubMed
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Randomized Controlled Trial with a reported sample of 283 on Autoimmune Research, published in Gastroenterology (2026) — summary generated from the PubMed abstract.
- 2026
- n = 283
Gastroenterology3 citations - Level ASystematic ReviewEurope PMC
Intraoperative Autologous Adipose-Derived Therapies and PRP as Add-On in the Surgical Treatment of Cryptoglandular and Crohn's Disease-Related Perianal Fistula-A Systematic Review
Systematic Review with a reported sample of 1017 on Autoimmune Research, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
- n = 1017
Bioengineering (Basel) - Level ASystematic ReviewEurope PMC
Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies
Systematic Review on Skin Aging, Chronic Inflammation, Autoimmune Research, published in Front Physiol (2026) — summary generated from the PubMed abstract.
- 2026
Front Physiol - Level ASystematic ReviewEurope PMC
Surgical interventions in inflammatory bowel disease: Indications, techniques, outcomes, and future directions
Systematic Review on Autoimmune Research, published in World J Gastrointest Pharmacol Ther (2026) — summary generated from the PubMed abstract.
- 2026
World J Gastrointest Pharmacol Ther - Level ASystematic ReviewEurope PMC
Management of Oro-Antral Communication: A Systemic Review of Diagnostic and Therapeutic Strategies
Systematic Review on Autoimmune Research, published in Diagnostics (Basel) (2025) — summary generated from the PubMed abstract.
- 2025
Diagnostics (Basel)5 citations